Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
What is your preferred dose and fractionation for managing an isolated unresectable pelvic nodal recurrence in a patient with locally advanced rectal cancer previously treated with TNT and LAR?
Related Questions
For inoperable cholangiocarcinoma, do you recommend up-front chemotherapy prior to offering SBRT or combination chemoradiation?
Would you recommend additional post-operative chemoradiation for a T2N1 proximal rectal cancer having received adjuvant capecitabine/oxaliplatin?
What would you include in your radiation field for a cT2N1 perianal squamous cell carcinoma in the setting of VIN3, CIN3 and AIN3?
What radiation therapy dose do you recommend for patients with high-grade neuroendocrine carcinoma of the esophagus and/or stomach who undergo chemoradiotherapy?
For patients with peritoneal carcinomatosis and minimal response to neoadjuvant chemotherapy, is there a benefit to palliative cytoreductive surgery followed by whole abdominal radiotherapy?
Does an esophageal stent impact your radiation treatment plan for a patient with non-metastatic GE junction adenocarcinoma?
In what situations would you treat a rectal mass as cancer despite negative biopsies?
A patient has unresectable, node-positive, oligometastatic gallbladder cancer -- when would you offer radiation?
Can palliative whole abdominal chemoradiation benefit nonoperative patients with extensive peritoneal carcinomatosis?
Do you ever utilize short-course radiation when lateral pelvic (extra-mesorectal) lymph nodes are involved?